From: Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib
Patient | Age | Gleason score | Stage | PSA (ng/ml) | Androgen ablation |
---|---|---|---|---|---|
01 | 57 | 9 (4 + 5) | pT3b N0 M0 | 7.88 | NO |
02 | 59 | 9 (4 + 5) | pT3a N0 M0 | 11.46 | NO |
03 | 58 | 7 (3 + 4) | pT3 N0 M0 | 8.03 | NO |